Allograft and tumor rejection have been shown to be mediated by both humoral (antibody) and cellular mechanisms (1, 2). However, the actual lymphocyte subpopulations involved in the cell-mediated rejection phenomenon remain to be identified. Cytolytic T lymphocytes (CTL) have been considered as a leading candidate because they have been shown to be generated during graft rejection (2), to be highly cytolytic for the relevant target cells in vitro (3), to inhibit tumor growth in vivo when admixed with tumor cells (4), and to accumulate selectively in grafts (5) and tumors (6). Nevertheless, recent reports question the role of CTL in vivo because precursor T cells of the Lyt-2-phenotype and not Lyt-2 + (cytolytic) cells were shown to mediate murine allograft (7) and rat syngeneic tumor rejection (8). With the possibility of deriving and maintaining in continuous culture clones of functionally active T cells, (9-12), the use of such cloned effector T cells should provide a direct means of resolving these contradictory observations.
cell cultures. Individual blast cells were micromanipulated into microwells containing irradiated P-815 tumor cells, irradiated syngeneie spleen cells, and a source of TCGF. 1 The resultant clones were tested for antigen-induced proliferation in the absence of added TCGF and for cytolytic activity on 51Cr-labeled P-815 tumor cells. Four autonomously proliferating cytolytic clones were selected, expanded in mass culture, and evaluated for the ability to induce tumor cell destruction i.p. in syngeneic, sublethally irradiated (650 rad) mice after intravenous injection (13, 14) . Tumor cells were initially labeled with 13tI-IUdR (18) and then 2 × 106 cells injected intraperitoneally. Tumor cell survival was monitored by whole-body counting techniques (14, 18) because ~alI label released from dead tumor cells is eliminated without reuse. The clones were further studied for specificity of cytolysis using several 5XCr-labeled tumor targets (3), antigen-induced production of lymphokines y-interferon (IFN-7) and macrophageactivating factor(s) (MAF) (19) , and cell surface phenotype using monoclonal antibodies and flow cytofluorographic analysis (20) .
Results
Fig . 1 shows that two of the four clones tested were able to mediate allogeneic tumor cell rejection after intravenous infusion, i.e., clones AL 15 ( Fig. 1 A) and AO 37 ( Fig. 1 B) . It should be noted that the two clones that were active in vivo were derived in independent experiments. Clone AL 15 cells induced a rapid, dose-dependent destruction of labeled tumor cells in the peritoneal cavity. 20 million cloned CTL injected intravenously resulted in the elimination by day 9 of >95% of the x31I-IUdR label initially injected (Fig. 1 A) . This dose of cloned T cells resulted in total protection of the mice, as assessed by survival 35 d later, in contrast to 5 × 106 cells that did not yield protection. The control group, which received 20 × 106 normal syngeneic spleen cells intravenously, retained 30-fold more radioactivity as measured on day 9, and all mice were dead with ascites by day 18 of experiment. CTL clone AO 37 gave similar results when tested in an independent experiment ( Fig. 1 B) , whereas clone AO 24 induced only a partial elimination of the labeled P-815 cells. Interestingly, CTL clone AL 33, which was isolated in an identical manner, failed to confer protection after injection of 20 × 106 cells intravenously (Fig. 1 B) . Table I summarizes several in vitro activities exhibited by the CTL clones described in Fig. I . All clones were highly cytolytic when tested on 51Cr-labeled P-815 (H-2 a) cells, the original stimulating alloantigen, and gave no detectable lysis of syngeneic EL-4 (H-2 b) or of third-party BW5147 (H-2 k) tumor target cells. All clones secreted considerable levels of the lymphokines IFN-y and MAF during the expansion phase in Costar 24-well plates. Fig. 2 depicts the cell surface phenotype of AL 15 and AO 37, the two clones that afforded protection, in addition to that of the nonprotective clone AL 33. All CTL clones expressed Lyt-2 but the expression of Lyt-1 was variable, as has been observed previously (11 ,12) .
Discussion
Although individual T cell clones specific for SRBC (21), y, influenza virus (22) , or parasite antigens (23) have been shown to function in vivo, this is the first report demonstrating the tumoricidal activity of alloreactive cloned Lyt-2 + cytolytic T cells in vivo after intravenous injection. Two out of the four autonomously proliferating CTL clones tested induced tumor cell destruction at a site distant from their injection. These results are in contrast to previous attempts in which six CTL clones failed to afford protection (13, 14) .
Because the CTL clones analyzed in this study proliferate autonomously in vitro in response to stimulation with alloantigens, in the absence of an added source of TCGF, Murine T cell clones were derived by micromanipulation techniques starting from a day 5 C57BL/6 (H-2~ anti-P-815 (H-2 a) allogeneic mixed leukocyte-tumor culture as described elsewhere.1 Cytolytic clones that proliferated autonomously when cultured with irradiated P-815 tumor cells plus irradiated T celldepleted syngeneic spleen cells in the absence of added TCGF were expanded in Costar 24-well plates and tested for ability to induce the rejection of 131I-IUdR-labeled P-815 tumor cells after intravenous injection (14, 18) (Fig. 1) , cell surface phenotype (20), (Fig. 2) , cytolytic activity on 51Cr-labeled tumor cells expressed as lytic units per 106 cloned T cells (3), and production of the lymphokines y-interferon (IFN-y) and macrophage-activation factor (MAF) expressed in units per ml relative to a standard preparation (19) . it is tempting to speculate that this selected subpopulation of Lyt-2 + CTL effector cells is especially suited to function in vivo after intravenous administration. It should, however, be noted that on a per cell basis, the protective CTL clones were 5-20-fold less efficient at inducing tumor cell rejection in vivo than were equally cytolytic Lyt-2 + cell populations recovered from day 5 mixed leukocyte cultures (13, 14) . Preliminary results using lalI-IUdR-labeled CTL clones demonstrate that up to 70% of the injected cells recovered are trapped in the lungs after intravenous injection (13, unpublished observations) . This may be one reason for the lower efficiency of cloned CTL cells vs. the day 5 mixed leukocyte culture effector cells. In addition, these observations may explain the positive results obtained in a previous report, whereby intravenous injection of an influenza-specific CTL clone protected mice from a nasal infection with virus (22) . The mechanism by which the injected effector cells accomplish the actual destruction of the tumor cells in vivo in this model system remains to be elucidated. Although it appears likely to be via direct cytolytic activity, a participation of radioresistant host cells, e.g., activated macrophages, cannot be ruled out. In addition, all CTL clones tested secreted considerable levels oflFN-y in vitro. Experiments are in progress to investigate the production of IFN-y in vivo in this model system. It also remains to be established whether differences in homing patterns between various T cell clones exist, and, if so, what role these differences might play in the functional activities displayed by these clones.
Summary
The in vivo activity of murine Lyt-2 + cytolytic T lymphocyte clones was assessed in a tumor allograft model system. Mice that had been sublethally irradiated 16 h previously were injected intraperitoneally with lalI-IUdR-labeled tumor cells. Simultaneously, various doses of four cytolytic T cell clones were injected intravenously and the mice monitored for tumor cell elimination by whole-body counting techniques. These four clones had been selected on the basis of their ability to proliferate in response to alloantigens in the absence of added T cell growth factor(s). With two of the four clones tested, rapid elimination of tumor cells within the peritoneal cavity was observed, as early as 48 h after intravenous injection of the cloned T cells.
